In the media
September 12, 2023

(French) Techbio: Owkin turns biotech on its head thanks to artificial intelligence

Thanks to AI and the data collected, Thomas Clozel, co-founder of Owkin, wants to treat patients with tumors.

‍

About Owkin

Owkin is an agentic AI company on a mission to explore complex biology to speed up and scale research for the creation of new treatments and diagnostics for patients. Owkin K, our AI co-pilot combines unparalleled access to multimodal data, cutting-edge AI to quantify biology and pioneering agentic AI to achieve Biological Artificial Superintelligence in the future. 

Press Kit

More like this

In the media
EY features Owkin's CEO Thomas Clozel in the "Grow Fast, Now What?" podcast (FR)
February 18, 2025
Button
In the media
Wall Street Journal features CEO Thomas Clozel
February 10, 2025
Button